Metabolic research
Tirzepatide
Lyophilized metabolic research compound
Tirzepatide is a dual GIP / GLP-1 receptor agonist reference point in metabolic research and comparative incretin pharmacology.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesSolo per ricerca di laboratorio. Non per uso umano o veterinario. Non destinato a diagnosticare, trattare, curare, mitigare o prevenire malattie.
Conservare sigillato, freddo, asciutto e protetto dagli sbalzi di calore. Conferma lo stoccaggio specifico del prodotto all'arrivo.
Imballato per garantire la stabilità del transito con supporto per gli ordini disponibile per le rotte con clima caldo.
Batch-linked certificate support is available through the documentation desk.
Contesto di ricerca
Profilo di ricerca Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist used extensively in incretin and metabolic pharmacology research. Experimental work examines receptor activation, cyclic-AMP signaling, receptor balance, pharmacokinetics, glucose regulation, lipid markers, and downstream metabolic endpoints. It is commonly compared with GLP-1-only compounds and with newer multi-receptor molecules such as retatrutide. Buyers typically select tirzepatide when the study design specifically needs a well-characterized dual-incretin reference without glucagon-receptor activity. A large human literature exists for the pharmaceutical molecule, but those findings do not verify the composition, sterility, safety, or performance of a separate research-use product.
Meccanismo proposto
Dual agonism at GIPR and GLP-1R, two class B G-protein-coupled receptors that signal largely through cyclic AMP. Proposed effects include glucose-dependent insulin secretion, altered glucagon signaling, delayed gastric emptying through GLP-1 pathways, and central appetite-related signaling.
Effetti riportati negli studi
- Receptor and animal studies report enhanced incretin signaling, improved glucose control, reduced food intake, and reduced body mass.
- Controlled human trials reported substantial reductions in glycated hemoglobin and body weight across studied populations.
- Frequently reported study effects include nausea, diarrhea, vomiting, constipation, and other gastrointestinal events.
Endpoint di ricerca comuni
GIPR and GLP-1R potency, cyclic AMP, insulin and glucagon response, gastric-emptying markers, glucose, HbA1c, lipids, food intake, body mass, pharmacokinetics, and tolerability.
Evidenze e limiti
Extensive receptor, animal, and controlled human evidence exists for regulated tirzepatide products. Catalog material is not represented as equivalent to an approved pharmaceutical product.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
Metabolico Peptide di ricerca
Retatrutide
Retatrutide is a metabolic research peptide studied as a triple agonist at GIP, GLP-1, and glucagon receptors. Published studies provide receptor-pharmacology and…
- Forma
- Polvere liofilizzata
- Quantità
- 15 mg
Fascia di prezzo: da 124.99 $ a 1,062.99 $ Scegli Questo prodotto ha più varianti. Le opzioni possono essere scelte nella pagina del prodotto -
Metabolico Peptide di ricerca
Mazdutide
Mazdutide sits in the GLP-1 / glucagon dual-agonist research lane, where interest centers on incretin signaling, energy expenditure, and metabolic markers.
- Forma
- Polvere liofilizzata
- Quantità
- 10 mg
Fascia di prezzo: da 138.99 $ a 590.99 $ Scegli Questo prodotto ha più varianti. Le opzioni possono essere scelte nella pagina del prodotto